2005
Altruism as a reason for participation in clinical trials was independently associated with adherence
Rosenbaum JR, Wells CK, Viscoli CM, Brass LM, Kernan WN, Horwitz RI. Altruism as a reason for participation in clinical trials was independently associated with adherence. Journal Of Clinical Epidemiology 2005, 58: 1109-1114. PMID: 16223653, DOI: 10.1016/j.jclinepi.2005.03.014.Peer-Reviewed Original ResearchConceptsClinical trialsBetter functional statusStudy medicationMedical regimenRecruitment of participantsClinical featuresStroke trialsFunctional statusWomen's EstrogenStratified analysisMultivariable regressionClinical researchEstrogenTrialsAdherenceBaseline featuresSocial supportFurther investigationWomenParticipantsAltruistic reasonsPossible contributionHigh levelsPlaceboMedications
2003
Pioglitazone Improves Insulin Sensitivity Among Nondiabetic Patients With a Recent Transient Ischemic Attack or Ischemic Stroke
Kernan WN, Inzucchi SE, Viscoli CM, Brass LM, Bravata DM, Shulman GI, McVeety JC, Horwitz RI. Pioglitazone Improves Insulin Sensitivity Among Nondiabetic Patients With a Recent Transient Ischemic Attack or Ischemic Stroke. Stroke 2003, 34: 1431-1436. PMID: 12730556, DOI: 10.1161/01.str.0000071108.00234.0e.Peer-Reviewed Original ResearchConceptsRecent transient ischemic attackTransient ischemic attackGlucose tolerance testOral glucose tolerance testHistory of diabetesInsulin sensitivityTolerance testIschemic attackNondiabetic patientsEligible subjectsIschemic strokeMean C-reactive protein concentrationC-reactive protein concentrationsEffectiveness of pioglitazoneMonths of therapyGlucose blood levelsYears of ageMean proportional increaseIndex eventBlood levelsPatientsPlaceboPioglitazoneStrokeDiabetes
1990
Treatment adherence and risk of death after a myocardial infarction
Horwitz RI, Viscoli CM, Donaldson R, Murray C, Ransohoff D, Horwitz R, Berkman L, Horwitz S, Ransohoff D, Sindelar J. Treatment adherence and risk of death after a myocardial infarction. The Lancet 1990, 336: 542-545. PMID: 1975045, DOI: 10.1016/0140-6736(90)92095-y.Peer-Reviewed Original ResearchConceptsRisk of deathTreatment adherenceMyocardial infarctionPoor adherersBeta-Blocker Heart Attack TrialPost-infarction mortalityHeart Attack TrialGood adherersTreatment regimenAttack TrialClinical severitySociodemographic featuresInfarctionAdherersAdherenceDeathMortalityRiskSeverityPlaceboRegimenSmokingPatientsPropranololTrials